Abstract
Background/Aims: Several dietary interventions, including those involving conjugated linoleic acid (CLA), slow progression of polycystic kidney disease (PKD) when initiated in the early stages of disease in Han:SPRD-cy rats. However, in humans, kidney disease is often undetected until extensive renal injury has developed. The objective of this study therefore was to determine whether initiating dietary CLA intervention in advanced PKD would slow disease progression. Methods: Adult male Han:SPRD-cy rats with advanced kidney disease were fed diets with or without 1% CLA for 16 weeks. Disease progression was assessed by serum urea, proteinuria, and creatinine clearance, and morphological and immunohistochemical measurements for pathologic change. Results: Renal injury was lower in the PKD rats given CLA compared to those given the control diet as indicated by a reduction in inflammation (42% less), fibrosis (28% less), oxidative damage (30% less) and proliferating cells (35% less). Diet had no effect on body, kidney, or liver weight, serum urea, serum creatinine, creatinine clearance, proteinuria, or cyst volume. Conclusions: Late dietary intervention with CLA reduced some disease-associated pathologies, but did not alter renal function in adult Han:SPRD-cy rats. The long-term anti-inflammatory, antioxidant, and antiproliferative benefits of CLA in advanced kidney disease remain to be determined.
Journal Section:
Original Paper
References
1.
Lysaght MJ: Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13 (suppl 1):S37–S40.
[PubMed]
2.
Gretz N, Ceccherini I, Kranzlin B, Kloting I, Devoto M, Rohmeiss P, Hocher B, Waldherr R, Romeo G: Gender-dependent disease severity in autosomal polycystic kidney disease of rats. Kidney Int 1995;48:496–500.
[PubMed]
3.
Aukema HM, Housini I: Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats. Kidney Int 2001;59:52–61.
[PubMed]
4.
Ogborn MR, Nitschmann E, Weiler HA, Bankovic-Calic N: Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int 2000;57:159–166.
[PubMed]
5.
Cahill LE, Peng CY, Bankovic-Calic N, Sankaran D, Ogborn MR, Aukema HM: Dietary soya protein during pregnancy and lactation in rats with hereditary kidney disease attenuates disease progression in offspring. Br J Nutr 2007;97:77–84.
[PubMed]
6.
Sankaran D, Bankovic-Calic N, Cahill L, Yu-Chen Peng, Ogborn MR, Aukema HM: Late dietary intervention limits benefits of soy protein or flax oil in experimental polycystic kidney disease. Nephron Exp Nephrol 2007;106:e122–e128.
[PubMed]
7.
Ogborn MR, Nitschmann E, Bankovic-Calic N, Weiler HA, Aukema HM: Effects of flaxseed derivatives in experimental polycystic kidney disease vary with animal gender. Lipids 2006;41:1141–1149.
[PubMed]
8.
Ogborn MR, Nitschmann E, Weiler H, Leswick D, Bankovic-Calic N: Flaxseed ameliorates interstitial nephritis in rat polycystic kidney disease. Kidney Int 1999;55:417–423.
[PubMed]
9.
Sankaran D, Bankovic-Calic N, Peng CY, Ogborn MR, Aukema HM: Dietary flax oil during pregnancy and lactation retards disease progression in rat offspring with inherited kidney disease. Pediatr Res 2006;60:729–733.
[PubMed]
10.
Edmunds JW, Jayapalan S, DiMarco NM, Saboorian MH, Aukema HM: Creatine supplementation increases renal disease progression in Han:SPRD-cy rats. Am J Kidney Dis 2001;37:73–78.
[PubMed]
11.
Ogborn MR, Sareen S: Amelioration of polycystic kidney disease by modification of dietary protein intake in the rat. J Am Soc Nephrol 1995;6:1649–1654.
[PubMed]
12.
Jayapalan S, Saboorian MH, Edmunds JW, Aukema HM: High dietary fat intake increases renal cyst disease progression in Han:SPRD-cy rats. J Nutr 2000;130:2356–2360.
[PubMed]
13.
Lu J, Bankovic-Calic N, Ogborn M, Saboorian MH, Aukema HM: Detrimental effects of a high fat diet in early renal injury are ameliorated by fish oil in Han:SPRD-cy rats. J Nutr 2003;133:180–186.
[PubMed]
14.
Tanner GA, Tanner JA: Citrate therapy for polycystic kidney disease in rats. Kidney Int 2000;58:1859–1869.
[PubMed]
15.
Parodi PW: Cows’ milk fat components as potential anticarcinogenic agents. J Nutr 1997;127:1055–1060.
[PubMed]
16.
Butz DE, Li G, Huebner SM, Cook ME: A mechanistic approach to understanding conjugated linoleic acid’s role in inflammation using murine models of rheumatoid arthritis. Am J Physiol Regul Integr Comp Physiol 2007;293:R669–R676.
[PubMed]
17.
Cheng WL, Lii CK, Chen HW, Lin TH, Liu KL: Contribution of conjugated linoleic acid to the suppression of inflammatory responses through the regulation of the NF-kappaB pathway. J Agric Food Chem 2004;52:71–78.
[PubMed]
18.
Huang G, Zhong X, Cao Y, Chen Y: Antiproliferative effects of conjugated linoleic acid on human colon adenocarcinoma cell line Caco-2. Asia Pac J Clin Nutr 2007;16(suppl 1):432–436.
[PubMed]
19.
Lampen A, Leifheit M, Voss J, Nau H: Molecular and cellular effects of cis-9, trans-11-conjugated linoleic acid in enterocytes: effects on proliferation, differentiation, and gene expression. Biochim Biophys Acta 2005;1735:30–40.
[PubMed]
20.
Ogborn MR, Nitschmann E, Bankovic-Calic N, Weiler HA, Fitzpatrick-Wong S, Aukema HM: Dietary conjugated linoleic acid reduces PGE2 release and interstitial injury in rat polycystic kidney disease. Kidney Int 2003;64:1214–1221.
[PubMed]
21.
Cowley BD Jr, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone VH 2nd: Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993;43:522–534.
[PubMed]
22.
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
[PubMed]
23.
Heinegard D, Tiderstrom G: Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta 1973;43:305–310.
[PubMed]
24.
Liu KL, Belury MA: Conjugated linoleic acid reduces arachidonic acid content and PGE2 synthesis in murine keratinocytes. Cancer Lett 1998;127:15–22.
[PubMed]
25.
Kavanaugh CJ, Liu KL, Belury MA: Effect of dietary conjugated linoleic acid on phorbol ester-induced PGE2 production and hyperplasia in mouse epidermis. Nutr Cancer 1999;33:132–138.
[PubMed]
26.
Ma DW, Field CJ, Clandinin MT: An enriched mixture of trans-10,cis-12-CLA inhibits linoleic acid metabolism and PGE2 synthesis in MDA-MB-231 cells. Nutr Cancer 2002;44:203–212.
[PubMed]
27.
Urquhart P, Parkin SM, Rogers JS, Bosley JA, Nicolaou A: The effect of conjugated linoleic acid on arachidonic acid metabolism and eicosanoid production in human saphenous vein endothelial cells. Biochim Biophys Acta 2002;1580:150–160.
[PubMed]
28.
Sankaran D, Bankovic-Calic N, Ogborn MR, Crow G, Aukema HM: Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol 2007;293:F821–F830.
[PubMed]
29.
Ogborn MR, Nitschmann E, Bankovic-Calic N, Weiler HA, Aukema HM: Dietary flax oil reduces renal injury, oxidized LDL content, and tissue n–6/n–3 FA ratio in experimental polycystic kidney disease. Lipids 2002;37:1059–1065.
[PubMed]
30.
Fair DE, Ogborn MR, Weiler HA, Bankovic-Calic N, Nitschmann EP, Fitzpatrick-Wong SC, Aukema HM: Dietary soy protein attenuates renal disease progression after 1 and 3 weeks in Han:SPRD-cy weanling rats. J Nutr 2004;134:1504–1507.
[PubMed]
31.
Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004;44:198–206.
[PubMed]
32.
Stenvinkel P: Inflammation in end-stage renal disease – a fire that burns within; in Ronco C, Brendolan A, Levin NW (eds): Cardiovascular Disorders in Hemodialysis. Contrib Nephrol. Basel, Karger, 2005, vol 149, pp 185–199.
33.
Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003;18:1272–1280.
[PubMed]
© 2008 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2008
You do not currently have access to this content.
